Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Next Phase: FDA Looks Beyond Three-Stage Drug Development Model

Executive Summary

The move towards mechanism-based therapies may call for clinical development programs that diverge from the traditional three-phase regime, FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb said

You may also be interested in...



Time To Be Creative With Adaptive Trials May Be Non-Pivotal Portion

BARCELONA, SPAIN - For companies looking to adopt adaptive trial designs, Merck VP of Biostatistics and Research Decision Sciences Jerald Schindler urged sponsors to frontload most of the adaptation in the non-pivotal portion of the clinical trial program and limit their own involvement in the adaptation that does take place during the pivotal portion

Time To Be Creative With Adaptive Trials May Be Non-Pivotal Portion

BARCELONA, SPAIN - For companies looking to adopt adaptive trial designs, Merck VP of Biostatistics and Research Decision Sciences Jerald Schindler urged sponsors to frontload most of the adaptation in the non-pivotal portion of the clinical trial program and limit their own involvement in the adaptation that does take place during the pivotal portion

Adaptive Trials Going Mainstream With Industry White Paper, FDA Guidance

Adaptive clinical trials in drug development are moving towards broader acceptance and feasibility with the upcoming publication of an industry white paper and an FDA workshop on the subject

Related Content

UsernamePublicRestriction

Register

PS046869

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel